Skip to main content

Table 2 Study Design and Patient Baseline Characteristics

From: Efficacy and tolerability of atypical antipsychotics for acute bipolar depression: a network meta-analysis

  Baseline Characteristics
Study n Duration Treatments Age Male Weighta Bipolar I MADRS CG-BP-S-Overall CGI-BP-S- Depression
Calabrese et al. 511 8 weeks Quetiapine IR 300 mg
Quetiapine IR 600 mg
Placebo
37.4 41.9% NR 66.9% 30.4 4.4 NR
Durgam et al. 571 8 weeks Cariprazine 0.75 mg
Cariprazine 1.5 mg
Cariprazine 3.0 mg
Placebo
41.9 37.7% 80.9 100.0% 30.6 4.4 NR
Earley et al.
Study 1)
480 6 weeks Cariprazine 1.5 mg
Cariprazine 3.0 mg
Placebo
42.8 40.8% 86.5 100.0% 30.6 4.5 NR
Earley et al.
Study 2)
490 6 weeks Cariprazine 1.5 mg
Cariprazine 3.0 mg
Placebo
43.6 37.3% 84.78 100.0% 31.4 4.5 NR
Li et al. 279 8 weeks Quetiapine XR 300 mg
Placebo
33.1 48.1% 64.5 50.9% 28.7 NR 4.5
Loebel et al.b 485 6 weeks Lurasidone 20–60 mg
Lurasidone 80–120 mg
Placebo
41.5 41.4% 77.2 100.0% 30.5 4.5 4.5
Lombardo et al. Study 1) 504 6 weeks Ziprasidone 40–80 mg
Ziprasidone 120–160 mg
Placebo
39.9 43.6% NR 100.0% 28.2 NR NR
Lombardo et al. Study 2) 381 6 weeks Ziprasidone 20–80 mg
Placebo
40.2 42.5% NR 100.0% 28.4 NR NR
McElroy et al. 582 8 weeks Quetiapine IR 300 mg
Quetiapine IR 600 mg
Placebo
38.5 36.9% 80.8 64.0% 26.9 4.2 NR
Suppes et al. 270 8 weeks Quetiapine XR 300 mg
Placebo
39.5 35.5% 88.8 80.4% 30.0 4.5 NR
Thase et al. 467 8 weeks Quetiapine IR 300 mg
Quetiapine IR 600 mg
Placebo
37.7 43.1% NR 67.4% 30.2 4.5 NR
Thase et al. (Study 1) 374 8 weeks Aripiprazole 5–30 mg
Placebo
39.0 37.5% 87.2 100.0% 28.8 NR 4.3
Thase et al. (Study 2) 375 8 weeks Aripiprazole 5–30 mg
Placebo
40.5 40.0% 86.8 100.0% 29.0 NR 4.4
Tohen et al. 747 8 weeks Olanzapine > 5 mgc
Placebo
42.0 41.5% NR 100.0% 32.0 NR 4.9
Tohen et al. 514 6 weeks Olanzapine 10–20 mg
Placebo
35.5 44.3% NR 100.0% 29.0 NR 4.5
Wang et al. 68 8 weeks Olanzapine 10–20 mg
Placebo
29.2 41.2% 63.9 100.0% 28.6 4.4 NR
Young et al. 647 8 weeks Quetiapine IR 300 mg
Quetiapine IR 600 mg
Placebo
42.2 41.6% 75.5 61.6% 28.3 4.3 NR
Yatham et al. 224 8 weeks Cariprazine 0.25–0.75 mg
Cariprazine 1.5–3.0 mg
Placebo
38.9 34.3% NR 72.7% 30.4 4.4 NR
  1. Abbreviations: NR Not reported, IR Immediate release, XR Extended release
  2. a Weight is reported in kilograms (kg)
  3. b Data not reported in the publication by Loebel et al., 2014 was supplemented by data from the Clinical Study Report for lurasidone (Sunovion Pharmaceuticals, data on file)
  4. c Mean daily dose: 9.7 mg
  5. d All dosing is reported in mg/day